New research reveals Small Colony Variants (SCVs) of P. aeruginosa to be a hallmark of chronic infection in cystic fibrosis (CF) patients. Results, published March 12th in the open-access journal PLoS Pathogens, suggest that SCV-mediated persistence might be a good target for antimicrobial Cystic

read more>>

Berlin -- Bayer Schering Pharma AG, Germany, announced today that an orphan drug designation has been granted by the U.S. Food and Drug Administration (FDA) for the ciprofloxacin dry powder inhaler (DPI) for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in cystic A s

read more>>

BETHESDA, Md. -- The U.S. Food and Drug Administration approved an important new inhaled antibiotic called Cayston® (aztreonam for inhalation solution) today for the treatment of cystic fibrosisThe drug was made possible by significant support from the Cystic Fibrosis Foundation, including a $

read more>>

RALEIGH, N.C. -- After a devastating loss of their five month old son to a genetically linked disease, a North Carolina couple finds hope for a healthy baby through an innovative technology called Preimplantation Genetic Diagnosis (PGDUsing embryo biopsy, PGD allows geneticists to screen for disor

read more>>

FOSTER CITY, Calif. -- Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Cayston(R)(aztreonam for inhalation solution) as a treatment to improve respiratory symptoms in cystic fibrosis (CF) patients with Cayston'

read more>>

In a study that could lead to new therapeutic targets for patients with the cystic fibrosis, a research team from the University of California, San Diego School of Medicine has identified a defective signaling pathway that contributes to disease severityIn the study, published in the journal Natur

read more>>

NESS ZIONA, Israel -- Kamada, a bio-pharmaceutical company engaged in the development, manufacturing and marketing of specialty life-saving therapeutics, announced today that it has enrolled the first patient into its pivotal clinical trial with its new breakthrough compound of inhaled alpha-1 The

read more>>

CAMBRIDGE, Mass. -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results from a preliminary analysis of data from a 28-day Phase 2a clinical trial of VX-809 in patients with cystic fibrosis (CF) who are homozygous for the F508del mutationVX-809, an oral investigational Cystic

read more>>

MARIETTA, Ga. -- Solvay Pharmaceuticals, Inc. announced today that Phase IIIb data published in the January issue of Clinical Therapeutics confirm that CREON® (pancrelipase) Delayed-Release Capsules significantly improves a key measure of fat absorption in children aged 7-11 years who have In

read more>>

The National Institute of General Medical Sciences (NIGMS) has awarded a $27 million, five-year contract to the Coriell Institute for Medical Research in Camden, N.J., to continue and expand operation of the NIGMS Human Genetic Cell Repository (HGCR). Under the new contract, the HGCR plans to "The

read more>>